The Blood and Marrow Transplant Clinical Trials Network (BMT CTN) conducts multi-institutional clinical trials to evaluate promising cellular therapies for patients facing life-threatening disorders. The goal to improve outcomes of therapies such as:
- Hematopoietic cell transplantation (HCT)
- Cellular vaccines
- Chimeric antigen receptor T-cells (CAR-T)
Established in 2001, renewed in 2006, 2011, and 2017, and funded by the National Heart, Lung, and Blood Institute (NHLBI) and the National Cancer Institute (NCI), the BMT CTN infrastructure facilitates participation of a large network of centers in trials available to patients in all regions of the United States of America (US).
The BMT CTN:
- Fosters the development of innovative concepts into well-designed trials that can effectively answer important scientific questions
- Supports the timely implementation and completion of trials
- Ensures protection of study participants (both donors and recipients)
- Provides high-quality data in an increasingly complex environment
- Ensures that the rules and regulations and ethical behavior guidelines outlined by federal regulatory bodies are followed
- Promotes timely publication of study results, advancing knowledge and impacting patient care
As an additional brief overview, please see the Slide Set here.